Table 1. . Candidate markers significantly associated with low-density lipoprotein cholesterol response to statin therapy.

SNP	Locus	Chr	Global Lipids Genetics Consortium					Genomic Investigation of Statin Therapy consortium
			EA	EA freq. (1000G)	Beta (SE)†	p-value	Other lipids	EA freq.	Beta (SE)‡	p-value
rs4420638	APOE	19	G	0.19	0.225 (0.008)	2 × 10-178	HDL-c, triglycerides, TC	0.17	0.025 (0.003)	3.9 × 10-15
rs629301	SORT1	1	T	0.79	0.167 (0.005)	5 × 10-241	HDL-c, TC	0.77	0.015 (0.003)	9.4 × 10-7
rs2072183	NPC1L1	7	C	0.24	0.039 (0.004)	7 × 10-16	TC	0.24	0.018 (0.005)	2.1 × 10-4

Listed variants are those with p-values smaller than the Bonferroni-corrected threshold of 8.5 × 10^-4 (i.e., 0.05/59) for the association with statin response.

^†Beta for effect on low-density lipoprotein cholesterol (LDL-c) levels, in standard deviations.

^‡Beta for difference between the natural log-transformed on- and off-treatment LDL-c levels adjusted for natural log-transformed off-treatment LDL-c, age-, sex- and study-specific covariates. A negative beta indicates a better statin response, a positive beta indicates a worse statin response.

Chr: Chromosome; EA: Effect allele for increased low-density lipoprotein cholesterol levels from the Global Lipids Genetics consortium; HDL-c: High-density lipoprotein cholesterol; freq: Frequency; SE: Standard error; TC: Total cholesterol.